Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Brenndörfer ED[au]:

Search results

Items: 21

1.

Long-term follow-up after cure from chronic hepatitis C virus infection shows occult hepatitis and a risk of hepatocellular carcinoma in noncirrhotic patients.

Lybeck C, Brenndörfer ED, Sällberg M, Montgomery SM, Aleman S, Duberg AS.

Eur J Gastroenterol Hepatol. 2019 Apr;31(4):506-513. doi: 10.1097/MEG.0000000000001316.

2.

Neonatal Exposure to Hepatitis C Virus Antigens in Uninfected Children Born to Infected Mothers.

Psaros Einberg A, Brenndörfer ED, Frelin L, Hallberg L, Sällberg M, Fischler B.

J Pediatr Gastroenterol Nutr. 2018 Jan;66(1):106-111. doi: 10.1097/MPG.0000000000001755.

PMID:
28953534
3.

Lack of Association Between Interleukin 28B Polymorphism and Vertical Transmission of Hepatitis C.

Psaros Einberg A, Duberg AS, Filipovich O, Nyström J, Zhirkov A, Brenndörfer ED, Frelin L, Rukoiatkina E, Lobzin Y, Sällberg M, Fischler B, Lutckii A.

J Pediatr Gastroenterol Nutr. 2017 Dec;65(6):608-612. doi: 10.1097/MPG.0000000000001711.

PMID:
28820758
4.

Hepatitis C Virus Nonstructural 3/4A Protein Dampens Inflammation and Contributes to Slow Fibrosis Progression during Chronic Fibrosis In Vivo.

Bansal R, Frelin L, Brenndörfer ED, Storm G, Prakash J, Sällberg M.

PLoS One. 2015 Jun 1;10(6):e0128466. doi: 10.1371/journal.pone.0128466. eCollection 2015.

5.

Long-term follow-up of successful hepatitis C virus therapy: waning immune responses and disappearance of liver disease are consistent with cure.

Hedenstierna M, Weiland O, Brass A, Bankwitz D, Behrendt P, Uhnoo I, Aleman S, Cardell K, Fryden A, Norkrans G, Eilard A, Glaumann H, Pietschmann T, Sällberg M, Brenndörfer ED.

Aliment Pharmacol Ther. 2015 Mar;41(6):532-43. doi: 10.1111/apt.13096. Epub 2015 Jan 28.

6.

The role of chemokines in hepatitis C virus-mediated liver disease.

Brass A, Brenndörfer ED.

Int J Mol Sci. 2014 Mar 18;15(3):4747-79. doi: 10.3390/ijms15034747. Review.

7.

Cleavage of the T cell protein tyrosine phosphatase by the hepatitis C virus nonstructural 3/4A protease induces a Th1 to Th2 shift reversible by ribavirin therapy.

Brenndörfer ED, Brass A, Karthe J, Ahlén G, Bode JG, Sällberg M.

J Immunol. 2014 Feb 15;192(4):1671-80. doi: 10.4049/jimmunol.1301077. Epub 2014 Jan 17.

8.

Containing "The Great Houdini" of viruses: combining direct acting antivirals with the host immune response for the treatment of chronic hepatitis C.

Ahlén G, Frelin L, Brenndörfer ED, Brass A, Weiland O, Chen M, Sällberg M.

Drug Resist Updat. 2013 Jul-Nov;16(3-5):60-7. doi: 10.1016/j.drup.2013.06.001. Epub 2013 Aug 2. Review.

9.

Non-structural 3 protein expression is associated with T cell protein tyrosine phosphatase and viral RNA levels in chronic hepatitis C patients.

Rahbin N, Frelin L, Aleman S, Hultcrantz R, Sällberg M, Brenndörfer ED.

Biochem Biophys Res Commun. 2013 Mar 29;433(1):31-5. doi: 10.1016/j.bbrc.2013.02.075. Epub 2013 Feb 27.

PMID:
23454379
10.

TCR-redirected human T cells inhibit hepatitis C virus replication: hepatotoxic potential is linked to antigen specificity and functional avidity.

Pasetto A, Frelin L, Aleman S, Holmström F, Brass A, Ahlén G, Brenndörfer ED, Lohmann V, Bartenschlager R, Sällberg M, Bertoletti A, Chen M.

J Immunol. 2012 Nov 1;189(9):4510-9. doi: 10.4049/jimmunol.1201613. Epub 2012 Sep 28.

11.

Hepatitis C virus-mediated modulation of cellular immunity.

Brenndörfer ED, Sällberg M.

Arch Immunol Ther Exp (Warsz). 2012 Oct;60(5):315-29. doi: 10.1007/s00005-012-0184-z. Epub 2012 Aug 22. Review.

PMID:
22911132
12.

Hepatitis C virus non-structural 3/4A protein interferes with intrahepatic interferon-γ production.

Brenndörfer ED, Brass A, Söderholm J, Frelin L, Aleman S, Bode JG, Sällberg M.

Gut. 2012 Apr;61(4):589-96. doi: 10.1136/gut.2010.232116. Epub 2011 Aug 3.

PMID:
21813471
13.

Heterologous T cells can help restore function in dysfunctional hepatitis C virus nonstructural 3/4A-specific T cells during therapeutic vaccination.

Chen A, Ahlén G, Brenndörfer ED, Brass A, Holmström F, Chen M, Söderholm J, Milich DR, Frelin L, Sällberg M.

J Immunol. 2011 May 1;186(9):5107-18. doi: 10.4049/jimmunol.1001790. Epub 2011 Mar 23.

14.

Electroporation: a promising method for the nonviral delivery of DNA vaccines in humans?

Frelin L, Brass A, Ahlén G, Brenndörfer ED, Chen M, Sällberg M.

Drug News Perspect. 2010 Dec;23(10):647-53. doi: 10.1358/dnp.2010.23.10.1513492. Review.

PMID:
21180650
15.

Anti-tumor necrosis factor α treatment promotes apoptosis and prevents liver regeneration in a transgenic mouse model of chronic hepatitis C.

Brenndörfer ED, Weiland M, Frelin L, Derk E, Ahlén G, Jiao J, Bode JG, Sällberg M.

Hepatology. 2010 Nov;52(5):1553-63. doi: 10.1002/hep.23870.

PMID:
20886569
16.

Interplay between host cell and hepatitis C virus in regulating viral replication.

Bode JG, Brenndörfer ED, Karthe J, Häussinger D.

Biol Chem. 2009 Oct;390(10):1013-32. doi: 10.1515/BC.2009.118. Review.

PMID:
19642875
17.

Nonstructural 3/4A protease of hepatitis C virus activates epithelial growth factor-induced signal transduction by cleavage of the T-cell protein tyrosine phosphatase.

Brenndörfer ED, Karthe J, Frelin L, Cebula P, Erhardt A, Schulte am Esch J, Hengel H, Bartenschlager R, Sällberg M, Häussinger D, Bode JG.

Hepatology. 2009 Jun;49(6):1810-20. doi: 10.1002/hep.22857.

PMID:
19475692
18.

Hepatitis C virus (HCV) employs multiple strategies to subvert the host innate antiviral response.

Bode JG, Brenndörfer ED, Häussinger D.

Biol Chem. 2008 Oct;389(10):1283-98. doi: 10.1515/BC.2008.147. Review.

PMID:
18713016
19.

Subversion of innate host antiviral strategies by the hepatitis C virus.

Bode JG, Brenndörfer ED, Häussinger D.

Arch Biochem Biophys. 2007 Jun 15;462(2):254-65. Epub 2007 Apr 16. Review.

PMID:
17467654
20.

Regulation of suppressor of cytokine signaling 3 (SOCS3) mRNA stability by TNF-alpha involves activation of the MKK6/p38MAPK/MK2 cascade.

Ehlting C, Lai WS, Schaper F, Brenndörfer ED, Matthes RJ, Heinrich PC, Ludwig S, Blackshear PJ, Gaestel M, Häussinger D, Bode JG.

J Immunol. 2007 Mar 1;178(5):2813-26.

21.

The hepatitis C virus and immune evasion: non-structural 3/4A transgenic mice are resistant to lethal tumour necrosis factor alpha mediated liver disease.

Frelin L, Brenndörfer ED, Ahlén G, Weiland M, Hultgren C, Alheim M, Glaumann H, Rozell B, Milich DR, Bode JG, Sällberg M.

Gut. 2006 Oct;55(10):1475-83. Epub 2006 Mar 9.

Supplemental Content

Loading ...
Support Center